IDEXX Laboratories, Inc. IDXX
519.26
5.87
1.14%
as of 25 Sep
- Market cap
- $40.2B
- P/E
- 36.2×
Follow IDXX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
IDEXX Laboratories, Inc. (IDXX) P/E ratio
As of 25 September 2026, IDEXX Laboratories, Inc. (IDXX) trades at a P/E ratio of 36.2×. Over the past ten years it has ranged from 31.2× (January 2016) to 85.8× (December 2020); the current reading is higher than 4% of that period. That is above the Diagnostics & Research industry median of 33.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 51.3× | 33.71% |
| FY2024 | 38.4× | (28.72%) |
| FY2023 | 53.9× | 7.70% |
| FY2022 | 50.0× | (33.63%) |
| FY2021 | 75.3× | 2.64% |
| FY2020 | 73.4× | 39.42% |
| FY2019 | 52.6× | 22.55% |
| FY2018 | 43.0× | (18.33%) |
| FY2017 | 52.6× | 10.93% |
| FY2016 | 47.4× | 34.94% |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 36.7× | (10.43%) |
| Mar 2026 | 41.0× | (20.10%) |
| Dec 2025 | 51.3× | 2.12% |
| Sep 2025 | 50.3× | 13.50% |
| 42 more quarters | Free account |
Against its own ten years
Low 31.2×
High 85.8×
Ten-year median
51.6×
Current reading's percentile
4
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 24.8× |
| IQV IQVIA Holdings Inc. compare | 33.3× |
| MTD Mettler-Toledo International, Inc. compare | 33.9× |
| A Agilent Technologies, Inc. compare | 33.9× |
| IDXX IDEXX Laboratories, Inc. | 36.2× |
| ILMN Illumina, Inc. compare | 50.4× |
| WAT Waters Corporation compare | 108× |
| Diagnostics & Research industry median | 33.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on IDXX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement